Higher-risk MDS: An update on emerging novel agents
touchTALKS for touchONCOLOGY
Listen to a leading expert in higher-risk myelodysplastic neoplasms (HR-MDS) discuss the impact that emerging treatment options may have on clinical practice. Dr David Sallman covers the latest updates to the classification of HR-MDS, the mode of action of emerging therapeutic agents and the most recent clinical evidence on their efficacy and safety.
The expert:
Dr David Sallman, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA
This touchPODCAST is for HCPs only.
This activity is funded by an independent medical education grant from Gilead…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.